As part of the LentiTHERAPY™ 3-hit strategy, SIRION developed and secured a technique to equip lentiviral capsids with single-chain antibody fragments to retarget the LV tropism towards specific cell surface markers.
The technique has been demonstrated for EGFR and CD-30 positive cells and is universally applicable to other antigen targets.
It enables controlled targeting of lentivirus towards a specific tissue, increasing transduction efficiency and reducing chances of unwanted off-target transductions.
Download the PDF here.
Link to the publication.
CONTACT US - to discover how this technology can help empower your R&D.